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The  efﬁcacy  and  safety  of  a spot-on  formulation  containing  10%  imidacloprid  and  2.5%  mox-
idectin  (Advocate®, Bayer  Animal  Health  GmbH,  Leverkusen,  Germany)  were  evaluated  in
a pilot  trial  for  the  treatment  of canine  nasal  capillariosis  caused  by Capillaria  boehmi  (syn.
Eucoleus  boehmi).  Sixteen  dogs  copromicroscopically  positive  for C.  boehmi  eggs  were  con-
ﬁrmed, either  by rhinoscopy  or species-speciﬁc  PCR-coupled  sequencing  assays,  as  being
affected  by nasal  capillariosis.  The  animals  were  randomly  allocated  to  two different  study
groups,  i.e.  one  (Group  T)  treated  with  Advocate® and  one  (Group  C)  left  untreated,  in  a ratio
of 1:1. The  animals  underwent  clinical  examination  and quantitative  copromicroscopy  for
C. boehmi  eggs  on  Days  -6 and  -2  (baseline)  and  Day 28  ± 2  (post-baseline).  Animals  in Group
T  received  Advocate® on  Day  0. On  Day 28 ±  2 the  efﬁcacy  of  the  treatment  (Group  T)  or
the  persistence  of the  infection  (Group  C)  was  conﬁrmed  by  rhinoscopy  or,  alternatively,
by  molecular  procedures.  Seven  of  the eight  dogs  in Group  T were  negative  on  Day  28  ± 2
(reduction  of  baseline  faecal  egg  counts  by  99.14%),  while  for one  dog  a  second  treatment  on
Day 28  ±  2  was necessary  to  clear  the infection,  as  demonstrated  on  Day  56 ± 2 (reduction
of baseline  faecal  egg  counts  by  100%  in  Group  T). Seven  animals  in  Group  C  received  a res-
cue dose  of  Advocate® on  Day 28  ± 2 and  scored  microscopically  and  molecularly  negative
for  the parasite  on  Day  56  ±  2, thus  increasing  the  reduction  of post-baseline  egg  counts  to
99.57% after  a single  administration.  These  promising  results  show  that  Advocate® spot-
on is an effective  formulation  for the  treatment  of  canine  nasal  capillariosis  under  ﬁeld
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conditions.
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1. Introduction
Capillaria boehmi (syn. Eucoleus boehmi) is a capillarid
nematode inhabiting the nasal turbinates and the frontal
and  paranasal sinuses of wild (e.g. foxes and wolves) and
domestic canids. Since the 1980s, when cases of “nasal
Open access under CC BY license.capillariosis” due to the closely related nematode Capil-
laria  aerophila (syn. Eucoleus aerophilus) were published
(Evinger et al., 1985; King et al., 1990), this parasite has
been  repeatedly described in the temperate regions of
 license.
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North America and Europe (Campbell and Little, 1991;
Schoning et al., 1993; Sréter et al., 2003; Gajewska et al.,
2004;  Baan et al., 2011). Nonetheless, knowledge of the
features of the disease, i.e. biological cycle, routes of trans-
mission, epidemiology, clinical impact, remains scanty
(Campbell and Little, 1991; Conboy, 2009). It is thought
that animals acquire the infection by ingesting larvated
eggs from the environment, and then larval stages migrate
to  the nasal cavities where they reach adulthood (Conboy,
2009). It has also been hypothesized, although never
demonstrated, that larval C. boehmi might develop in earth-
worms  acting as facultative intermediate or paratenic hosts
(Campbell  and Little, 1991), as has also been speculated for
C.  aerophila (Conboy, 2009; Traversa et al., 2010).
The infection caused by C. boehmi in dogs is either
subclinical or clinically manifest when the damage in the
epithelium of the nasal turbinates and sinuses induces
rhinitis characterized by symptoms of varying severity, i.e.
sneezing,  reverse sneezing, nasal discharge and impair-
ment of scenting ability (i.e. hypo- or anosmia) (Evinger
et  al., 1985; Campbell and Little, 1991; Piperisova et al.,
2010;  Baan et al., 2011; Veronesi et al., 2013). Furthermore,
C. boehmi has recently been recognised as a potential cause
of  intracranial disease and meningoencephalitis in dogs as
a  result of aberrant migration in the cranial cavity (Clark
et  al., 2013).
Although C. boehmi is rarely detected in dogs, recent
reports have suggested the spread of symptomatic infec-
tions  in both the Americas and Europe (Piperisova et al.,
2010;  Baan et al., 2011; Di Cesare et al., 2012a; Magi et al.,
2012;  Clark et al., 2013; Veronesi et al., 2013). It is thus
possible that C. boehmi is another non-intestinal nematode
of  dogs which is potentially emerging in several areas, as
recently  indicated for other respiratory parasites affecting
dogs  and/or cats (Traversa et al., 2010).
There is signiﬁcant merit in evaluating effective thera-
peutic options for this neglected disease, in that no drug
has  been approved for the treatment of C. boehmi infection.
The  little information available is related to a few single
clinical cases or small case series, most of which have eval-
uated  macrocyclic lactones (MLs) with promising results
(Evinger et al., 1985; Conboy, 2009; Veronesi et al., 2013;
Conboy et al., 2013). In particular, moxidectin was  recently
shown to be effective in a single dog infected by C. boehmi
(Veronesi et al., 2013) and in cats infected with the closely
related C. aerophila (Traversa et al., 2012).
Fig. 1. Copromicroscopic examination: eggs of Capillaria boehmi showing the typi
the  embryo and the egg shell. Original magniﬁcation 40×. Scale bar: 20 m.tology 200 (2014) 133– 138
The pilot trial described here evaluated the efﬁcacy
and safety of a spot-on formulation containing 10% imida-
cloprid/2.5% moxidectin (Advocate®, Bayer Animal Health
GmbH,  Leverkusen, Germany) in the ﬁeld treatment of
canine  nasal capillariosis.
2.  Materials and methods
2.1.  Pre-inclusion screening
The  study was carried out from November, 2012 to
June, 2013 in Italy following pre-inclusion screening of 287
dogs.  The majority of the animals were kept in public or
private  kennels located in Central Italy and in particular
in the municipalities of Latina and Rome (Latium region),
Perugia (Umbria Region), Cesena (Emilia Romagna region)
and  Chiusi (Tuscany region), selected on the basis of pre-
vious  history of suspected or diagnosed cases of nasal
capillariosis. The others were dogs referred to veterinary
hospitals for disorders of the upper respiratory tract or pri-
vately  owned dogs whose faeces were examined by routine
copromicroscopy at the Parasitological Unit of the Faculty
of  Veterinary Medicine in Perugia.
A faecal sample from each dog was  collected and
examined for C. boehmi eggs using a qualitative copromi-
croscopic concentration-ﬂotation procedure with a sugar
solution  with 1.200 speciﬁc gravity (s.g.) (Sloss et al., 1994).
The  eggs of C. boehmi were identiﬁed on the basis of the
following morphological and morphometric features: size
55.30  ± 1.30 × 32.40 ± 2.60 m,  a typical space between
the embryo and the wall, asymmetry of the non-ringed
plugs and the appearance of the egg shell characterized by
several  tiny pits (Di Cesare et al., 2012a).
All dogs which scored positive for eggs of C. boehmi
(Fig. 1) at this qualitative copromicroscopical screening
were submitted to conﬁrmatory rhinoscopy to demon-
strate the presence of the parasite in situ and/or to nasal
ﬂushing. If the owners did not consent the rhinoscopic
procedure, a conﬁrmatory species-speciﬁc PCR-coupled
sequencing assay was used on the faecal samples. Brieﬂy,
the  genomic DNA was extracted from each faecal sample
and  then subjected to a PCR assay speciﬁc for the mito-
chondrial cox1 gene Capillariinae Subfamily as described
previously (Di Cesare et al., 2012b). Additionally, DNA
extracted from three adult specimens of C. boehmi micro-
scopically identiﬁed at the species level was  subjected
cal asymmetry of bipolar plugs and a small, clear to golden space between
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o the aforementioned PCR (Di Cesare et al., 2012b). The
mplicons from both the adults and faecal eggs were
equenced and the sequences were compared with each
ther.
Dogs  treated within the last two months with any
nthelmintic drug, affected by severe systemic diseases
r  in generally poor health were excluded from the
rial.
.2. Animal enrolment, clinical examinations and
nthelmintic treatments
Of  the 287 dogs, 19 scored positive in copromicroscopy
nd rhinoscopy/conﬁrmatory PCR, and 16 were enrolled in
he  study with the owner’s consent. The enrolled dogs con-
isted  of nine privately owned animals and seven kennelled
ogs  of variable breed and gender with an age ranging
rom 1.5 to 10 years and weighing between 13.5 and
5  kg.
The  dogs underwent two quantitative faecal egg counts
FECs) using a McMaster technique (Sloss et al., 1994) on
ays  -6 and -2 to ensure that a pre-existing C. boehmi infec-
ion  was still present at the time of treatment. At the same
ime  as the faecal samples were obtained, a pre-treatment
linical examination was conducted to detect symptoms
ompatible with nasal capillariosis. An individual form was
ompleted  for each dog to record its medical history and
linical  data.
The  16 dogs were allocated to two different study
roups, i.e. Group T treated with Advocate® and the control
roup  C left untreated, according to a randomized block
esign  in a ratio of 1:1.
Dogs  in Group T were treated topically on Day 0 with a
ingle  dose of Advocate®, with a second treatment planned
or  those which were still positive for C. boehmi eggs on
ay  28 ± 2. All treated animals were clinically examined for
–4  h post-treatment to evaluate the safety and the poten-
ial  side effects of the spot-on formulation administered.
he occurrence of adverse effects (AE) and serious adverse
ffects  (SAE) was to be registered.
Dogs  in Group C which were still infected on Day 28 ± 2
eceived a rescue dose of Advocate® and were examined for
he  persistence of the infection on Day 56 ± 2 as described
bove. Another clinical examination was conducted for all
xamined  dogs on Days 28 ± 2 and 56 ± 2.
.3.  Post-treatment evaluation
On  Day 28 ± 2 two faecal samples were collected from
he  16 dogs and underwent post-treatment examination
sing the McMaster technique. Additionally, where per-
itted  by the owners, another rhinoscopy was performed
o  conﬁrm the efﬁcacy of the treatment (T Group) and the
ersistence of the parasite (C Group). Alternatively, the
bove-mentioned molecular procedures were applied to
aecal  samples collected for post-treatment.
Dogs in both the groups which tested positive on Day
8  ± 2 underwent two further copromicroscopic examina-
ions  on Day 56 ± 2.ology 200 (2014) 133– 138 135
2.4.  Data analysis
The  primary efﬁcacy criterion was the reduction of base-
line  eggs per gram (EPG) counts on Day 28 ± 2. The mean
value from the two  faecal counts performed in the pre-
treatment assessment (i.e. two  examinations on Day -6 and
-2)  was used as the baseline value, and the mean value of
EPG  counts on Day 28 ± 2 was  used as the post-baseline
value. The analysis of the efﬁcacy criterion was performed
on  a log-transformed scale using an analysis of covariance
adjusted for the baseline EPG counts.
Geometric means (GeoMeans) were calculated using
the  log-arithmetic mean (ArithMean) of the EPG counts of
each  animal. The GeoMean was calculated using the log-
ArithMean of the EPG count of each animal, adding a “1” to
the  EPG count for each animal in both the Groups in view of
the  “zero” values of some EPG counts. This constant “1” was
subtracted from the resultant calculated geometric mean
prior  to calculating percentage efﬁcacy.
The difference between the GeoMeans for EPG before
and after the treatment was expressed as percentage efﬁ-
cacy  (%) using the following formula:
% Efﬁcacy
=  100
(
GeoMean EPG at baseline − GeoMean EPG at post-baseline
GeoMean at baseline
)
Treatment was deemed effective if a percentage reduc-
tion of at least 90% was achieved along with a signiﬁcant
difference (p < 0.05, two-sided) between the EPG counts in
Group  C and Group T.
3.  Results
3.1. Dogs
All  dogs were treated appropriately in accordance with
the  protocol, none were removed from the study subse-
quent to inclusion for any reason, and all were included in
the  efﬁcacy calculations.
Seven  out of the eight dogs in Group T were negative
for C. boehmi eggs on Day 28 ± 2. The single positive dog
received a second treatment and was  examined again on
Day  56 ± 2.
All eight animals in Group C were still infected on com-
pletion of the study, and seven received a rescue dose of
Advocate® and were re-examined on Day 56 ± 2.
3.2. Efﬁcacy evaluation
The  ArithMean EPG count at baseline was  450 (±159.09)
and 581.25 (±112.87) in Groups T and C respectively, with
no  signiﬁcant difference in FECs between the two groups
(p  = 0.51).
The baseline EPG values in dogs in Group T were reduced
from 450 (±159.09) to 48.12 (±48.12) on Day 28 ± 2 and
to  0 on Day 56 ± 2, corresponding to an efﬁcacy of 99.14
and  100% respectively (Table 1). Efﬁcacy on Day 28 ± 2 (i.e.
after  a single administration of Advocate®) increased to
99.57%  after data from the rescue treatment received by
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Table 1
Evaluation of the efﬁcacy of a 10% imidacloprid/2.5% moxidectin spot-on formulation (Advocate® , Bayer Animal Health) against Capillaria boehmi.
Study period and statistics T group C group Differencea
Actual Change Actual Change
Baseline EPG
ArithMean (SD) 450 (159.09) 581.2 (112.77) F = 4.6 p = 0.51
95%  CI 315/585 457.8/704.6
Min/Max 200/1525 275/1200
Median 262.5 512.5
GeoMean 345.58 513.65
Post-baseline I EPG
ArithMean  (SD) 48.12 (48.12) −401.88 (110.97) 584.37 (114.46) 3.17 F = 4.6 p = 0.0007
95%  CI 36.82/59.42 −487.13/−316.63 532.07–636.37 2.87–3.47
Min/Max 0/385 −200/−1140 225/1125 −50/25
Median  0 −262.5 537.5 25
GeoMean 2.10 −343.48 504.70 −8.95
Percentage of efﬁcacy (95% CI) 99.14% (95.3–99.9%)
Post-baseline II EPG
ArithMean  (SD) 0 (0) −450 (−159.09) F = 4.6 p = 0.00016
95%  CI 0 −315/−585
Min/Max 0 −200/−1525
Median 0 −262.5
GeoMean 1 −344.58
Percentage of efﬁcacy (95% CI) 100% (97.4–100%)
Group T: eight naturally infected dogs; Group C: eight control dogs left untreated; Baseline EPG: maximum actual faecal egg counts in terms of C. boehmi
eggs  per gram of faeces pre-treatment (Days -6 and -2); Post-baseline I EPG: faecal egg counts post-treatment (Day 28 ± 2); Post-baseline II EPG: faecal
5% conﬁdence interval; Min: minimum; Max: maximum; ArithMean: arithmeticegg  counts post-treatment (Day 56 ± 2); SD: standard deviation; 95% CI: 9
mean;  GeoMean: geometric mean.
a Difference between groups from ANOVA adjusted for baseline.
seven control dogs were included. In Group C no evident
difference between mean EPG before (581.2 ± 112.77) and
after  (584.37 ± 114.46) treatment was demonstrated, with
a  corresponding change of 1.74% from baseline.
The difference between Group T and Group C with
regard to the change in EPG from baseline was 502.60 on
Day  28 ± 2 and 504.70 on Day 56 ± 2, which is statistically
signiﬁcant (p < 0.01) (Table 1).
3.3.  Clinical ﬁndings and outcome
Neither AEs nor SAEs were recorded in any of the treated
dogs.
On  Days -6 and -2 all the dogs in Group T and ﬁve in
Group C showed various respiratory symptoms on clini-
cal  examination, i.e. repeated sneezing (n = 9 dogs), reverse
sneezing (n = 2), nasal discharge (n = 4), epistaxis (n = 3),
hypo-/anosmia (n = 3), cough (n = 4) and scratching of the
nasal  region (n = 1) (Table 2).
Clinical  signs disappeared in seven of the eight symp-
tomatic animals in Group T and in ﬁve animals which
received the rescue treatment four weeks after the ini-
tial  treatment had been given. The dog in Group T which
received a second treatment was still symptomatic on Day
28  ± 2 but had fully recovered on Day 56 ± 2 (Table 3).
3.4. Rhinoscopy and molecular procedures
The presence of nasal capillariosis in animals which
were positive for C. boehmi eggs at the faecal examination
was conﬁrmed by endoscopic and/or molecular approaches
carried out at both pre- and post-treatment evaluations.
All dogs in Group T scored positive for adult stages of
C.  boehmi at rhinoscopy (Fig. 2) and/or for eggs followingFig. 2. Rhinoscopy: adult stages of Capillaria boehmi embedded in the
mucosa of the middle meatus of a naturally infected dog in Group T.
nasal ﬂushing, whereas all the eight animals in Group C
tested  positive in molecular procedures applied to faecal
samples where consent to the endoscopic procedure had
not  been given.
Post-treatment rhinoscopy was  performed for six dogs
in  Group T because the owners of two dogs did not give
their  consent to additional anaesthesia. The negative result
of  copromicroscopy was  conﬁrmed by the aforementioned
genetic assays for these two animals and for the control
animals which received rescue treatment.
Of the eight dogs in Group T, seven were negative
on endoscopy (n = 6) and in the conﬁrmatory PCR (n = 1)
conducted on Day 28 ± 2, while one dog that scored PCR-
positive on Day 28 ± 2 was negative at the examination
performed on Day 56 ± 2 (Table 3).
All  seven dogs in Group C which were given rescue
treatment scored negative on copromicroscopy and con-
ﬁrmatory PCR performed on Day 56 ± 2 (Table 3). Thus, a
second  administration of Advocate® was  not necessary for
these  dogs.
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Table 2
Clinical signs in sixteen dogs naturally infected with Capillaria boehmi at baseline.
Group Symptoms
None Presence
Repeated
sneezing
Reverse
sneezing
Nasal
discharge
Epistaxis  Hypo/Anosmia Cough Scratching of
the  nasal
region
T N. animals (%) 0 6 2 7 1 2 2 0
C  N. animals (%) 3 3 0 4 2 1 2 1
Total  N. (%) 3 (18.75%) 9 (56.25%) 2 (12.5%) 11 (68.75%) 3 (18.75%) 3 (18.75%) 4 (25%) 1 (6.25%)
Group T: eight naturally infected dogs; Group C: eight control dogs left untreated.
Table 3
Pre-  and post-treatment clinical ﬁndings and outcome, and positivity or negativity on rhinoscopy and molecular diagnosis in the 16 dogs included in the
ﬁeld  trial.
Group ID Pre-treatment Post-treatment
Day 28 ± 2 Day 56 ± 2
CS Rhinoscopy PCR CS Rhinoscopy PCR CS Rhinoscopy PCR
T 1  + +AW + NF NP − −AW − NF NP
2 + +AW + NF NP − −AW − NF NP
3 + −AW + NF NP − −AW − NF NP
4 + −AW + NF NP − −AW − NF NP
6 + −AW + NF NP + NA + − NA −
13  + −AW + NF NP − NA −
14 + +AW + NF NP − −AW − NF NP
15 + +AW + NF NP − −AW − NF NP
C 5 + NA + + NA + − NA −
7  + NA + + NA + − NA −
8  − NA + − NA + − NA −
9  + NA + + NA + − NA −
10  − NA + − NA + − NA −
11  + NA + + NA + − NA −
12  + NA + + NA + − NA −
16  − NA + − NA + − NA −
Group T: group treated; Group C: control group left untreated; ID: animal identiﬁcation; CS: clinical signs; NA: not allowed; NP: not performed; +NF:
p r C. boeh
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iositive  nasal ﬂushing for C. boehmi eggs; −NF: negative nasal ﬂushing fo
or  adult specimens of C. boehmi; +: positivity on rhinoscopy or molecula
All sequences obtained from PCR amplicons generated
rom faeces proved to be the appropriate species C. boehmi,
.e.  ∼100% homology with sequences obtained from micro-
copically identiﬁed adult parasites.
. Discussion and conclusion
This  study, although preliminary, showed that
dvocate® spot-on is safe and effective in the treatment of
atural  canine infection by C. boehmi.
The efﬁcacy of this anthelmintic formulation was  inves-
igated on the basis of copromicroscopic results conﬁrmed
y  rhinoscopy, nasal ﬂushing or a molecular assay. A sensi-
ivity  <100% cannot be ruled out for the McMaster method.
he  negative results of copromicroscopy in treated dogs
ere  therefore conﬁrmed by the absence of adult parasites
r  eggs on rhinoscopy or nasal ﬂushing, and of DNA in the
CR  procedure. A similar PCR assay recently validated for
ulmonary capillariosis due to C. aerophila may  identify
ositive faecal samples which are negative on copromi-
roscopy (Di Cesare et al., 2012b). Thus, the negative results
ound  in this study for parasitic DNA in the faeces may
n  fact signify the absence of C. boehmi in treated dogs.mi eggs; +AW:  positive for adult specimens of C. boehmi; −AW:  negative
sis; −: negativity on rhinoscopy or molecular diagnosis.
The  consistency between the McMaster method and the
other  approaches demonstrates that the former is a reli-
able  approach to diagnosing the infection. Additionally, the
diagnostic  sensitivity of the test was assured by repeated
quantitative examinations at each of the pre- and post-
treatment sampling times.
At  present there is no drug licensed for the treatment of
C.  boehmi infection in dogs, and the therapeutic regimens
attempted have been derived empirically (Conboy, 2009;
Baan  et al., 2011; Veronesi et al., 2013). Moreover, some
information derives from dated cases of nasal capillario-
sis  in which a likely misidentiﬁcation between C. aerophila
and  C. boehmi occurred (Evinger et al., 1985; King et al.,
1990).  The efﬁcacy of benzimidazoles (BZs) and MLs  has
been  described in single clinical cases, although the proto-
cols  used were not entirely satisfactory due to controversial
or varying efﬁcacy in treating clinical signs and stopping
egg shedding.
The administration of fenbendazole at 50 mg/kg/day for
ten  consecutive days in a single dog produced fast recovery
from  clinical signs and assured negative faecal examina-
tions at six weeks post-treatment (King et al., 1990). The
same  protocol led to the regression of clinical signs in a
y Parasi138 F. Veronesi et al. / Veterinar
dog which, however, was re-infected few weeks later. A
second  two-week course of fenbendazole was successful,
and coprophagia was also prevented to avoid re-infection
(Baan et al., 2011). While treatment with 0.5–1 mg/kg of
milbemycin oxime was ineffective in the treatment of a
dog  with a history of chronic sneezing and intermittent
post-exercise nasal discharge due to C. boehmi, a dosage of
2  mg/kg was effective, producing clinical recovery and ces-
sation  of faecal egg shedding (Conboy et al., 2013). The ﬁrst
evaluation  of a single dose of 0.2 mg/kg ivermectin by the
oral  route demonstrated the clinical recovery of an infected
dog  and cessation of egg shedding for 8 and 4 months post-
treatment, respectively (Evinger et al., 1985). However, the
same  treatment protocol also demonstrated an inconsis-
tent  reduction of clinical signs and the inability to eliminate
faecal egg shedding, despite consecutive doses (King et al.,
1990;  Baan et al., 2011).
A  recent report has described the usefulness of mox-
idectin (2.5 mg/kg) in inducing clinical recovery and
negative faecal results, along with prevention of re-
infection for four consecutive months, in a dog infected
by  C. boehmi (Veronesi et al., 2013). The present results
conﬁrm that a single administration of spot-on moxidectin
is  a suitable choice for the effective treatment of canine
nasal capillariosis. In fact, in the present trial only one
dog  remained infected after a single administration of the
molecule,  although this did succeed in treating the para-
sitic  infection after a second dose. Interestingly, this dog
showed  the highest pre-treatment EPG values in Group
T,  thus suggesting that two administrations are necessary
to  clear the infection in animals which may  be heavily
infected. Although preliminary, the present study has ﬁlled
gaps  in the knowledge of treatment of canine nasal capil-
lariosis by evaluating moxidectin in a case series of infected
dogs.
Apart  from its high level of efﬁcacy, Advocate® also
has the advantages of single-dose administration and
easy-to-apply topical delivery as compared to other
molecules (e.g. fenbendazole) which require consecutive
administrations.
In  conclusion, Advocate® spot-on in dogs naturally
infected by E. boehmi is a safe and effective option for treat-
ing  clinical signs and eliminating egg shedding and adult
parasites in situ. GCP studies are warranted to further eval-
uate  the efﬁcacy and safety of Advocate® in the therapy of
canine  infection with C. boehmi. These studies could also
be  worthwhile in terms of preventing the disease, given
that  infected dogs are at high and frequent risk of recur-
rent  infections (King et al., 1990; Baan et al., 2011; Veronesi
et  al., 2013).
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